BR112015017692B1 - Uso de um vírus do sarampo infeccioso, método para preparar células e usos - Google Patents

Uso de um vírus do sarampo infeccioso, método para preparar células e usos Download PDF

Info

Publication number
BR112015017692B1
BR112015017692B1 BR112015017692-5A BR112015017692A BR112015017692B1 BR 112015017692 B1 BR112015017692 B1 BR 112015017692B1 BR 112015017692 A BR112015017692 A BR 112015017692A BR 112015017692 B1 BR112015017692 B1 BR 112015017692B1
Authority
BR
Brazil
Prior art keywords
cells
pdcs
deltac
tumor
cancer
Prior art date
Application number
BR112015017692-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015017692A2 (pt
Inventor
Frédéric Tangy
Chantal Combredet
Jean-Baptiste GUILLERME
Jean-François FONTENEAU
Marc Gregoire
Original Assignee
Institut Pasteur
Centre National De La Recherche Scientifique
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Universite De Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale (Inserm), Universite De Nantes filed Critical Institut Pasteur
Publication of BR112015017692A2 publication Critical patent/BR112015017692A2/pt
Publication of BR112015017692B1 publication Critical patent/BR112015017692B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation
    • C12N2760/18462—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112015017692-5A 2013-01-24 2014-01-20 Uso de um vírus do sarampo infeccioso, método para preparar células e usos BR112015017692B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305086.4A EP2759301A1 (en) 2013-01-24 2013-01-24 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
EP13305086.4 2013-01-24
PCT/EP2014/051063 WO2014114605A1 (en) 2013-01-24 2014-01-20 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in cancer therapy

Publications (2)

Publication Number Publication Date
BR112015017692A2 BR112015017692A2 (pt) 2019-11-19
BR112015017692B1 true BR112015017692B1 (pt) 2021-11-03

Family

ID=47683672

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017692-5A BR112015017692B1 (pt) 2013-01-24 2014-01-20 Uso de um vírus do sarampo infeccioso, método para preparar células e usos

Country Status (11)

Country Link
US (3) US9889193B2 (cg-RX-API-DMAC7.html)
EP (2) EP2759301A1 (cg-RX-API-DMAC7.html)
JP (1) JP6382223B2 (cg-RX-API-DMAC7.html)
CN (1) CN107223055A (cg-RX-API-DMAC7.html)
BR (1) BR112015017692B1 (cg-RX-API-DMAC7.html)
CA (1) CA2898370C (cg-RX-API-DMAC7.html)
DK (1) DK2948157T3 (cg-RX-API-DMAC7.html)
ES (1) ES2700749T3 (cg-RX-API-DMAC7.html)
PL (1) PL2948157T3 (cg-RX-API-DMAC7.html)
RU (1) RU2700083C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014114605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
CN107085095A (zh) * 2017-03-02 2017-08-22 江苏华冠生物技术股份有限公司 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法
US11633441B2 (en) 2017-12-01 2023-04-25 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
CN117323421A (zh) * 2022-06-24 2024-01-02 中国医学科学院医学生物学研究所 一种流感病毒介导的抗肿瘤疫苗及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
EP2058003A1 (en) * 2007-10-10 2009-05-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Medicaments and methods for treating mesothelioma
EP2420242A1 (en) * 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
US9399062B2 (en) * 2011-01-18 2016-07-26 Christopher D. Richardson PVRL4 (Nectin4) is a receptor for measles virus
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)

Also Published As

Publication number Publication date
JP2016506722A (ja) 2016-03-07
US9889193B2 (en) 2018-02-13
US10980873B2 (en) 2021-04-20
CN107223055A (zh) 2017-09-29
BR112015017692A2 (pt) 2019-11-19
ES2700749T3 (es) 2019-02-19
WO2014114605A1 (en) 2014-07-31
JP6382223B2 (ja) 2018-08-29
RU2015128913A (ru) 2017-03-02
DK2948157T3 (en) 2019-01-07
US10314905B2 (en) 2019-06-11
US20180221469A1 (en) 2018-08-09
US20200016260A1 (en) 2020-01-16
PL2948157T3 (pl) 2019-03-29
US20150359873A1 (en) 2015-12-17
EP2948157A1 (en) 2015-12-02
EP2948157B1 (en) 2018-10-10
EP2759301A1 (en) 2014-07-30
CA2898370C (en) 2020-01-14
CA2898370A1 (en) 2014-07-31
RU2700083C2 (ru) 2019-09-12

Similar Documents

Publication Publication Date Title
Gauvrit et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response
JP6740340B2 (ja) 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用
US10980873B2 (en) Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy
JP2023081859A (ja) コロナウイルスワクチン
TW201606079A (zh) 以減毒新城雞瘟病毒為特徵之組合物及用於治療贅瘤形成之方法
JP2021176862A (ja) デングウイルス及び樹状細胞による併用療法のための組成物及び方法
US20110268764A1 (en) Immune response inducing preparations
US9636395B2 (en) Medicaments and methods for treating mesothelioma
JP2020528890A (ja) 腫瘍を治療するためのウイルス
Zhu et al. Recombinant Chinese Hu191 measles virus exhibits a significant antitumor activity against nephroblastoma mediated by immunogenic form of apoptosis
CN110636853A (zh) 重组溶瘤病毒
JP5884100B2 (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するDIs株由来組換えワクシニアウイルス
NL2031110B1 (en) Recombinant adeno-associated virus vector, recombinant adeno-associated virus aav8-pd1 and use thereof
HK40097472A (en) Coronavirus vaccine
WO2023025899A2 (en) Delivery system for targeting genes of the interferon pathway
KR20250004666A (ko) 종양 용해성 유전자 개변 홍역 바이러스의 신규용도

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2547 DE 29/10/2019 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/01/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: INSTITUT PASTEUR (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; NANTES UNIVERSITE (FR)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2863 DE 18/11/2025 POR TER SIDO INDEVIDA.